advice for community hematologists when prescribing bispecific antibodies for multiple myeloma
Published 2 weeks ago • 68 plays • Length 3:07Download video MP4
Download video MP3
Similar videos
-
2:39
advancements in bispecific and trispecific antibodies for the treatment of lymphoma
-
2:17
the role of car t-cell therapy for treating myeloma in the era of bispecific antibodies
-
1:45
using the available repertoire of bispecific antibodies for treating multiple myeloma
-
1:49
outpatient management of patients with multiple myeloma treated with bispecific antibodies
-
2:38
approaching the treatment of patients with lbcl who relapse after bispecific antibodies
-
58:00
know your myeloma immunotherapy: teclistamab and other bispecifics
-
8:07
multiple myeloma is no longer a dead end: dr pravas mishra
-
3:15
what is the best diet for myeloma patients to build a strong immune system?
-
2:25
advancements and challenges in bispecific antibodies for the treatment of b-nhl
-
3:37
bispecific antibodies in multiple myeloma: their current role and the future
-
1:33
sequencing and the management of adverse events when administering bispecifics for myeloma
-
3:38
outcomes for patients with multiple myeloma who have had first-line monoclonal antibody exposure
-
2:12
risk of infection and mitigation strategies in patients with myeloma treated with bispecifics
-
1:48
the potential of bispecific antibody-containing combinations in patients with b-cell lymphomas
-
2:26
factors to consider when selecting myeloma patients for antibody therapy
-
1:15
safety & efficacy of bispecific antibodies in multiple myeloma: teclistamab & elranatamb
-
3:02
optimal treatment strategies for multiple myeloma
-
3:01
moving towards a more dynamic strategy to determine eligibility for sct in multiple myeloma
-
5:58
what myeloma patients need to know about bispecific antibodies
-
1:57
the safety and efficacy of iberdomide for the treatment of multiple myeloma
-
3:08
selecting therapeutics for treating early relapses in multiple myeloma
-
1:40
barriers that remain in finding a cure for multiple myeloma